KeyInvest Weekly Hits

Friday, 26.10.2018

  • Topic 1: Low-volatility strategy - Get off the roller coaster
  • Topic 2: Gold - The crisis currency moves up

Low-volatility strategy
Get off the roller coaster

Trade disputes, Brexit chaos and a controversial Italian budget proposal – these three factors have been making life uncomfortable for investors recently. They have also caused the turbulence on the global equity markets to rise sharply. Collective sentiment is reflected in implied volatilities. The range of fluctuation priced into options shot up at the start of the fourth quarter (see chart). In an environment like this, investment strategies targeting stocks with relatively low volatility could come into their own once again. The same goes for the K Switzerland Low Volatility NTR Index. Year to date this underlying has extended its long-term outperformance of the SMITM.1 A PERLES (symbol: SOLVZU) can give investors exposure to this benchmark in their portfolio.

Performance on the Swiss equity market is something of a roller coaster at the moment. The SMITM gained 5.6% between July and September 2018. This was the strongest performance the domestic blue chip index had posted since the first three months of 2013. But it was not enough for a breakout to the upside. Instead, recent weeks have seen the SMITM move down smartly. Shortly before the end of October the performance for the month was down 3.5%.1 Over extended periods these ups and downs in prices reduce returns. Academic studies have demonstrated that portfolios of relatively low-volatility stocks beat the broader market in the long term. This puts them at odds with traditional capital market theory, which assumes that the more risk an investor takes, the higher the return on a diversified portfolio. Robert Haugen and James Heins documented the “low volatility anomaly” as long ago as 1972. Twenty years after that, US researchers Eugene Fama and Kenneth French published a three-factor model. One of the characteristics this featured as driving returns was low volatility.

This is the starting point for the K Switzerland Low Volatility Index. The benchmark is based on smart beta methodology. In other words, the composition of the index does not weight the constituent stocks by market capitalization in the traditional way. Instead, it implements a low-volatility strategy in the Swiss equity market. Candidates for inclusion come from the 300 companies with the largest capitalization. Every month a filter selects the 20 stocks with the lowest range of price fluctuations from this universe. Weightings are based on inverse volatility, so the less a stock price moves compared to the other index constituents, the higher its percentage. The weighting of a single component is capped at 10% to avoid cluster risk.
The current composition of the K Switzerland Low Volatility Index reflects the full range of the domestic equity market: there are nine stocks in the SMITM and 11 second and third-liners. These include several shares which have been little affected by the recent market turbulence. Helvetia Holding, PSP Swiss Property and Lindt & Sprüngli, for example, have risen year to date¹.

Opportunities: The PERLES is listed on SIX (symbol: SOLVZU) and is a way of taking a diversified position in the 20 lowest-volatility stocks on the Swiss equity market. The product replicates the K Switzerland Low Volatility Index for an annual management fee of 1.00%. Any dividends on the constituents are reinvested net in the underlying. The term is limited to a total of seven years, but this can be extended by the same period.

Risks: This product does not have capital protection. With a PERLES, losses are incurred if the underlying index falls. Investors in structured products are also exposed to issuer risk, which means that the capital invested may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

K Switzerland Low Volatility NTR Index vs. SMI™ TR Index
(5 years; for illustrative purposes only; figures in %)¹

The K Switzerland Low Volatility Index has risen in the past. Over a five-year period the smart beta benchmark has outperformed the SMITM considerably.

Source: UBS AG, Bloomberg

As of 25.10.2018

Helvetia Holding vs. Lindt & Sprüngli vs. PSP Swiss Property
(5 years; for illustrative purposes only; figures in %)¹

Insurance, chocolate and real estate are the industries Helvetia, Lindt & Sprüngli and PSP operate in, all of which have contributed to the recent outperformance of the K Switzerland Low Volatility Index.

Source: UBS AG, Bloomberg

As of: 25.10.2018

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

PERLES on the K Switzerland Low Volatility Index

Symbol SOLVZU
SVSP Name Tracker-Certifikat
SPVSP Code 1300
Underlying K Switzerland Low Volatility Index
Ratio 1:1
Currency CHF
Administration fee 1.00% p.a.
Participation 100%
Expiry 17.04.20123
Issuer UBS AG, London
Bid/Ask CHF 251.25 / 252.75
 

K Switzerland Low Volatility Index – Composition as of 31.08.2018

Helvetia PSP Swiss Property
Baloise Swiss Prime Site
Nestlé Swiss Re
Kuehne & Nagel Swiss LIfe
Swisscom SGS
Lindt & Sprüngli Schindler Holding
Geberit Roche Holding
Givaudan EMS Chemie
Partners Group Barry Callebaut
Zurich Insurance Pargesa Holding
 

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 25.10.2018

Market overview

Index Quotation Week¹
SMI™ 8’724.61 -0.3%
SLI™ 1’358.59 -2.9%
S&P 500™ 2’656.10 -5.5%
Euro STOXX 50™ 3’130.33 -3.5%
S&P™ BRIC 40 3’744.33 -3.2%
CMCI™ Compos. 949.39 -1.6%
Gold (troy ounce) 1’231.10 USD 0.3%

¹ Change based on the closing price of the previous day compared to the closing price a week ago.

SMI™ vs. VSMI™ 1 year

smi vs vsmi

The VSMI™ Index is calculated since 2005. It shows the volatility of the stocks within the SMI™ index. A portfolio which reacts only to changes in volatility instead of volatility itself is relevant for the calculation. Thereby, the VSMI™ methodology uses the squared volatility, known as variance, of the SMI options with remaining time to expiry of 30 days traded at the Eurex.

Source: UBS AG, Bloomberg

As of: 25.10.2018

Gold
The crisis currency moves up

The weather may have been nice in October, but things were less agreeable on the stock market. As discussed on the preceding pages, equity market corrections pushed volatility up sharply. At the same time, gold showed signs of life. The crisis currency has risen 3.4% since the end of September.¹ Logically, the ETC (Symbol: CGCCIU) on the UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index broke out to the upside of its downward technical trend. This participation product makes it possible to take roll-optimized positions in the precious metal.

Most investor showed little interest in gold as a safe haven until the end of the third quarter. The steep increase in interest rates in the USA and the associated strength of the dollar weighed on it in particular. While the greenback itself remains in demand as a crisis currency and is holding up at a high level, the gold price has shot up in recent weeks. Clearly the rise in general uncertainty factors has driven increasing numbers of investors to switch to risk-off mode. The situation in Italy is of special concern for financial markets. The government of the right-wing Lega party and the populist Five Star movement is planning to raise far more new debt in 2019 than its predecessor had indicated. The EU Commission has rejected Rome’s draft proposal, something which has never happened before in the history of the Eurozone. “If trust is eroded, all Member States take damage, our union takes damage,” said Commission Vice-President Valdis Dombrovskis of this unprecedented step. Italy now has three weeks to react to the criticism and submit a new budget for 2019 to Brussels. (Source: Thomson Reuters media report, 23 October 2018)

Opportunities: The ETC (Symbol: CGCCIU) on the UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index allows investors to diversify their portfolios simply and cheaply. The product underlying replicates the gold price by using various futures contracts. As is typical for the CMCI index family, positions are taken across the entire forward curve and all liquid maturities. A hedging mechanism ensures that fluctuations between the US dollar (the currency gold is priced in) and the Swiss franc (the product currency) are neutralized every month.

Risks: This product does not have capital protection. With an ETC, losses are incurred if the underlying index falls. Investors in structured products are also exposed to issuer risk, which means that the capital invested may be lost if UBS AG becomes insolvent, regardless of the performance of the underlying.

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Gold (in US dollars per fine ounce) 5 years¹

Source: UBS AG, Bloomberg

As of: 25.10.2018

ETC on the UBS Bloomberg CMCI Gold CHF Monthly Hedged TR Index

Symbol CGCCIU
SVSP Name Tracker-Certifikat
SPVSP Code 1300
Underlyings UBS Bloomberg CMCI Gold Monthly Hedged TR Index
Currency CHF
Ratio 10:1
Administration fee 0.38% p.a.
Participation 100%
Expiry Open End
Issuer UBS AG, London
Bid/Ask CHF 74.75 / 75.10
 

More UBS products and further information on the risks and opportunities are available at ubs.com/keyinvest.

Source: UBS AG, Bloomberg

As of: 25.10.2018

¹) Please be aware that past performance does not indicate future results.
²) The conditions of ETTs are reviewed on a yearly basis and can be adjusted with a deadline of 13 months after the announcement.

This material has been prepared by UBS AG or one of its affiliates («UBS»). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments (“Instruments”). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document (“Information”) except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information. This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.
This information is communicated by UBS AG and/or its affiliates («UBS»). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this website relates (the «Structured Product»). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this website. UBS’s trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS’s hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the under-lying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS’s prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.
© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.